TCT 2019 | PARTNER 2A at 5 Years: In Intermediate-Risk Patients, TAVR Is Still Head-to-Head with Surgery

Courtesy of the SBHCI.

The 2-year results of the PARTNER 2A trial showed that transcatheter aortic valve implantation has a result similar to that of surgery in patients with aortic stenosis and intermediate surgical risk. We lacked long-term data, both clinical and related to prosthesis function.

Highlights TCT 2019

Now, at TCT 2019, researchers presented the 5-year data for this work, information long awaited by interventional cardiologists.

The PARTNER 2A trial randomized 2032 patients with severe aortic stenosis and intermediate surgical risk to transcatheter aortic valve replacement (TAVR) or surgical replacement in 57 sites between 2011 and 2013. Patients were eligible for transfemoral access (n = 1550) or transapical/transaortic access (n = 482). The primary endpoints analyzed were all-cause death or stroke, and the analysis also included echocardiography results, so as to count with durability data.


Read also: TCT 2019 | Mitral Valve-in-Valve: 1-Year Results for Sapien 3 in Mitral Valve Replacement for Degenerated Bioprostheses.


At 5 years, death and stroke were 47.9% in the TAVR group and 43.4 % in the surgery group (p = 0.21).

For patients who received the prosthesis through transfemoral access, there were no differences at 5 years (44.5% vs. 42%; p = 0.8); however, in patients who required transapical/transaortic access, surgery had better outcomes (59.3% for TAVR vs. 48.3% for surgery; p = 0.03).

At 5 years from implantation or surgery, over 95% of patients in both groups were free of aortic valve reintervention, with an advantage favoring surgery (99.4% vs. 96.8%).

The gradients for bioprostheses at 30 days, 1, 2, 3, 4, and 5 years were similar for both strategies (around 10 mmHg). It was different for aortic regurgitation, with an advantage in favor of surgery (33.3% vs. 6.3%; p < 0.001). The severity of aortic regurgitation was related with all-cause death, which occurred in 64.8% of patients with moderate or severe regurgitation, 48.7% of patients with mild regurgitation, and 41.1% of patients with no regurgitation (p < 0.001).

Courtesy of the SBHCI.

Original title: Outcomes from a Randomized Trial of Transcatheter vs. Surgical Aortic Valve Replacement in Intermediate-Risk Patients with Severe Aortic Stenosis.

Presenter: Vinod H. Thourani.

Link to the SBHCI publication AQUÍ

partner-2

Original title: PARTNER 2A – 5-Year: Outcomes From A Randomized Trial Of Transcatheter Vs. Surgical Aortic Valve Replacement In Intermediate-Risk Patients With Severe Aortic Stenosis.

Author of the original article: Vinod H. Thourani.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

One-Year Results of ENCIRCLE: Percutaneous Mitral Valve Replacement in Patients Ineligible for Surgery or TEER

Symptomatic mitral regurgitation (MR) in patients who are not candidates for surgery or transcatheter edge-to-edge repair (TEER) remains a highly complex clinical scenario associated...

Can Coronary CT Angiography Replace Invasive Coronary Angiography in Pre-TAVI Coronary Assessment?

Coronary artery disease coexists in approximately half of patients undergoing transcatheter aortic valve implantation, making coronary assessment prior to the procedure essential. Invasive coronary...

Valve-in-Valve in Small Surgical Aortic Bioprostheses: Balloon-Expandable or Self-Expanding? Three-Year Results from the LYTEN Trial

Dysfunction of small surgical aortic bioprostheses represents a challenging scenario for transcatheter aortic valve replacement in the valve-in-valve setting, due to the higher incidence...

Can TAVI Be Safely Performed in Patients With Bicuspid Aortic Valve?

Bicuspid aortic valve (BAV) represents an anatomical challenge for transcatheter aortic valve replacement (TAVR) due to the frequent presence of elliptical annuli, fibroc calcific...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Sheathless Femoral Impella: A New Strategy to Reduce Vascular Complications in High-Risk PCI?

Patients with complex coronary artery disease or cardiogenic shock undergoing percutaneous coronary intervention (PCI) may benefit from the hemodynamic support provided by percutaneous ventricular...

OCT- and IVUS-Guided Coronary Angioplasty in Acute Coronary Syndrome: Long-Term Clinical Outcomes

Percutaneous coronary angioplasty (PCI) in patients with acute coronary syndrome (ACS) has reduced mortality in the acute phase. However, recurrent ACS and target vessel...

One-Year Results of ENCIRCLE: Percutaneous Mitral Valve Replacement in Patients Ineligible for Surgery or TEER

Symptomatic mitral regurgitation (MR) in patients who are not candidates for surgery or transcatheter edge-to-edge repair (TEER) remains a highly complex clinical scenario associated...